NeoGenomics, Inc. Deferred Foreign Income Tax Expense (Benefit)
NeoGenomics, Inc. (NEO) reported Deferred Foreign Income Tax Expense (Benefit) of -$3.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-17
- NeoGenomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2025 was -$3.39M.
- NeoGenomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2024 was -$2.24M.
- NeoGenomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2023 was -$9.75M.
- NeoGenomics, Inc. deferred foreign income tax expense (benefit) for fiscal 2022 was -$15.21M.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$3.39M 10-K · filed 2026-02-17 |
| 2024-12-31 | -$2.24M 10-K · filed 2026-02-17 |
| 2023-12-31 | -$9.75M 10-K · filed 2026-02-17 |
| 2022-12-31 | -$15.21M 10-K · filed 2025-02-18 |
| 2021-12-31 | -$7.48M 10-K · filed 2024-02-20 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-24 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
| 2018-12-31 | $115.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | -$115.00K 10-K · filed 2020-02-28 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |